|Videos|January 5, 2017

Is the Prevalence of Powassan Virus Increasing in Humans?

Holly Frost, MD, pediatrics physician scientist at the Marshfield Clinic Research Foundation, in Minocqua, Wisconsin, discusses whether or not the prevalence of Powassan virus is increasing in humans.

Holly Frost, MD, pediatrics physician scientist at the Marshfield Clinic Research Foundation, in Minocqua, Wisconsin, discusses whether or not the prevalence of Powassan virus is increasing in humans.

Interview Transcript (slightly modified for readability)

“Powassan [virus] is an emerging infection, and so, we know that the amount of Powassan that we’re been seeing in ticks has been increasing, and the seroprevalence in mammals has been increasing. [As a result], it’s likely that we’re going to see more of this as time progresses.

I think we need to do further studies looking at what the true clinical presentation of Powassan virus is. We know very little aside from patients who have neurologic disease, because that’s the population we’ve really tested before. We also need to learn more about how patients [who] have coinfection with other tick-borne diseases, such as patients [who] have both Lyme disease and Powassan at the same time present, and if they have a higher severity of illness, or if their illness lasts for a longer period of time.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.